Figure 4From: Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]Plasma fibrinogen up to 36 months since trial entry (adjusted for baseline differences between groups).Back to article page